Peony Yu - FibroGen Chief Medical Officer
FGEN Stock | USD 1.17 0.10 7.87% |
Executive
Dr. K. Peony Yu, M.D., is Chief Medical Officer of the Company. She served as our Vice President of Clinical Development from December 2008 until April 2016 when she was promoted to Chief Medical Officer. Dr. Yu brings to us expertise in design and execution of all phases of clinical development programs, including clinical and regulatory strategy, interactions with regulatory authorities in the United States and European Union, as well as experience with successful leadership of clinical teams. Prior to joining us, Dr. Yu was Vice President of Clinical Research at Anesiva, Inc., where she was responsible for management of clinical research, statisticsdata management, clinical operations, and medical affairsmedical information for all clinical programs, including the latestage clinical development and approval of Zingo, a drugdevice combination for pain management. Prior to Anesiva, Dr. Yu was Director, Clinical Development at ALZA Corporation where she was Global Clinical Lead for IONSYS, a drugdevice combination for postoperative pain, and led a successful New Drug Application resubmission with the U.S. Food and Drug Administration and multiple interactions with European regulatory authorities resulting in marketing approval in 25 European countries. Prior to ALZA, Dr. Yu held previous posts at Pain Therapeutics, Inc. and at Elan Pharmaceuticals since 2016.
Age | 54 |
Tenure | 8 years |
Address | 409 Illinois Street, San Francisco, CA, United States, 94158 |
Phone | 415 978 1200 |
Web | https://www.fibrogen.com |
FibroGen Management Efficiency
The company has return on total asset (ROA) of (0.3554) % which means that it has lost $0.3554 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1579) %, meaning that it created substantial loss on money invested by shareholders. FibroGen's management efficiency ratios could be used to measure how well FibroGen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 19th of April 2024, Return On Tangible Assets is likely to grow to -0.64. In addition to that, Return On Capital Employed is likely to grow to -1.24. At this time, FibroGen's Total Assets are very stable compared to the past year. As of the 19th of April 2024, Non Current Assets Total is likely to grow to about 146.7 M, while Other Assets are likely to drop 0.95.Similar Executives
Showing other executives | EXECUTIVE Age | ||
Josie Yang | AVROBIO | N/A | |
Arturo Molina | Sutro Biopharma | 59 | |
Mario Orlando | Gossamer Bio | N/A | |
John SullivanBolyai | Hepion Pharmaceuticals | 76 | |
Catriona Yale | Akero Therapeutics | 52 | |
Lionel Carnot | Merus BV | 49 | |
Xiaolin Wang | Revolution Medicines | 53 | |
Ellen Broug | Merus BV | N/A | |
Ravi Upasani | Biomea Fusion | N/A | |
Robert MBA | Verastem | N/A | |
Luisa SalterCid | Gossamer Bio | 59 | |
Lauren MBA | Day One Biopharmaceuticals | 48 | |
Kirsten Dupuis | AVROBIO | N/A | |
Amy Wireman | Biomarin Pharmaceutical | N/A | |
Jonathan Day | Biomarin Pharmaceutical | N/A | |
Caryn Peterson | Gossamer Bio | 65 | |
Steven JD | AVROBIO | 62 | |
Scott Biller | Agios Pharm | 62 | |
John Cavan | Hepion Pharmaceuticals | 66 | |
Michael Howell | Zura Bio Limited | 47 | |
Janet Graesser | VaxcyteInc | N/A |
Management Performance
Return On Equity | -10.16 | ||||
Return On Asset | -0.36 |
FibroGen Leadership Team
Elected by the shareholders, the FibroGen's board of directors comprises two types of representatives: FibroGen inside directors who are chosen from within the company, and outside directors, selected externally and held independent of FibroGen. The board's role is to monitor FibroGen's management team and ensure that shareholders' interests are well served. FibroGen's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, FibroGen's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Kearns, Independent Director | ||
Kirk MBA, Chief Officer | ||
Rahul Kaushik, Technical Development | ||
Jorma Routti, Independent Director | ||
Mr JD, Chief Officer | ||
Jeffrey Edwards, Director | ||
Barry Berkowitz, Founder | ||
James Schoeneck, Independent Director | ||
David DeLucia, Vice Relations | ||
Toshinari Tamura, Independent Director | ||
Jeffrey Henderson, Director | ||
K Yu, Vice President - Clinical Development | ||
Peony Yu, Chief Medical Officer | ||
Gerald Lema, Director | ||
Juan Graham, Chief Officer | ||
Roberto Rosenkranz, Independent Director | ||
Thomas Neff, Founder, Chairman and CEO | ||
Enrique Conterno, CEO Director | ||
Frank Valone, Chief Medical Officer | ||
Kalevi Kurkijarvi, Independent Director | ||
Christine Chung, Senior Operations | ||
Suzanne Blaug, Independent Director | ||
Thane Wettig, CEO Director | ||
Maykin Ho, Independent Director | ||
Elias Kouchakji, Drug Devel | ||
Rory Riggs, Independent Director | ||
Julian Stern, Corporate Secretary, Director, Member of Audit Committee and Member of Compensation Committee | ||
KinHung Yu, Chief Medical Officer | ||
Karen Bergman, Vice President Investor Relations and Corporate Communications | ||
Tricia Stewart, Chief Officer | ||
Pat Cotroneo, CFO, Vice President - Finance | ||
MPH MD, Ex Officer | ||
John Hunter, Chief Officer |
FibroGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is FibroGen a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -10.16 | ||||
Return On Asset | -0.36 | ||||
Profit Margin | (1.92) % | ||||
Operating Margin | (3.81) % | ||||
Current Valuation | 102.28 M | ||||
Shares Outstanding | 98.77 M | ||||
Shares Owned By Insiders | 6.36 % | ||||
Shares Owned By Institutions | 71.45 % | ||||
Number Of Shares Shorted | 5.19 M | ||||
Price To Earning | 97.67 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for FibroGen Stock analysis
When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Bonds Directory Find actively traded corporate debentures issued by US companies |
Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.536 | Earnings Share (2.92) | Revenue Per Share 1.518 | Quarterly Revenue Growth (0.21) | Return On Assets (0.36) |
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.